| |||||||||

Industry (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
|
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
||
| Operating Income | 0 | 0 | 0 | 0 | 0 | |||
| Gross Profit | 46.7B | 44.9B | 42.8B | 39.3B | 42.6B | |||
| Total Revenues | 52.5B | 51.3B | 48.4B | 48.4B | 48.3B | |||
| Net Income | 11.4B | 8.09B | 19.3B | 8.14B | 8.10B | |||
| Gross Margin | 85.6% | 84.7% | 84.2% | 76.8% | 83.2% | |||
| Research and Development Expense | 7.51B | 7.26B | 7.60B | 8.09B | 7.95B | |||
| R&D/Sales Ratio | 14.6% | 15.3% | 15.7% | 16.7% | 16.5% | |||
| Number of Drugs | 0 | 47.0 | 47.0 | 34.0 | 0 | |||
| Number of Drugs in Phase I | 0 | 30.0 | 29.0 | 22.0 | 26.0 | |||
| Number of Drugs in Phase II | 0 | 12.0 | 18.0 | 16.0 | 19.0 | |||
| Number of Drug Approvals | 0 | 3.00 | 2.00 | 3.00 | 2.00 | |||
| New Drug Applications | 0 | 6.00 | 2.00 | 2.00 | 8.00 | |||
| Revenue - Japan/Asia | 0 | 0 | 0 | 0 | 7.17B | |||
| Revenue - Lyrica | 0 | 0 | 0 | 0 | 2.57B | |||
| ||||||